FDA Approves Lenalidomide Capsules in 2.5mg, 20mg Strengths
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.
VRd may be an effective front-line treatment for patients with multiple myeloma.